No

Sclerosing Agent

Treatment of small, uncomplicated varicose veins of the lower extremities; endoscopic sclerotherapy in the management of bleeding esophageal varices

C

Arterial disease, thrombophlebitis, hypersensitivity to sodium tetradecyl or any component, valvular or deep vein incompetence, phlebitis, migraines, cellulitis, acute infections; bedridden patients; patients with uncontrolled systemic disease such as diabetes, toxic hyperthyroidism, tuberculosis, asthma, neoplasm, sepsis, blood dyscrasias, and acute respiratory or skin diseases

Buerger's disease, peripheral arteriosclerosis, avoid extravasation; observe for hypersensitivity/anaphylactic reaction

Percentage unknown: Headache, urticaria; sloughing and tissue necrosis following extravasation; nausea, vomiting, mucosal lesions, esophageal perforation, discoloration at the site of injection, ulceration at the site, pain at injection site, pulmonary edema, asthma

Chemically incompatible with heparin

Store at controlled room temperature in a well-closed container; protect from light

Acts by irritation of the vein intimal endothelium

I.V.: Test dose: 0.5 mL given several hours prior to administration of larger dose; 0.5-2 mL in each vein, maximum: 10 mL per treatment session; 3% solution reserved for large varices

Inject slowly

No information available to require special precautions

No effects or complications reported

Notify physician if chest pain, shortness of breath, or heat, pain, or tenderness in lower extremities

Observe for signs and symptoms of embolism

Injection, as sulfate: 1% [10 mg/mL] (2 mL); 3% [30 mg/mL] (2 mL)